Ultima-Oxa 10 mg 50 Tablets Ultima Pharma USA

Product Overview

Ultima Pharma USA’s Oxa 10 mg presents oxandrolone, featuring unique 2-oxa-5α-androstane structure preventing aromatization while maintaining DHT-derived anabolic potency characteristic of 17α-alkylated steroids (~9-13 hour half-life), in capsule-shaped white scored tablets precisely replicating discontinued Oxandrin 10 mg (BTG Pharmaceuticals) morphology for seamless institutional catalog integration across DEA-registered reseller networks. The 50-tablet HDPE bottle configuration supports CIII-compliant inventory reconciliation protocols mandated under 21 CFR 1304.22 requiring triennial audits and monthly Schedule III reporting for institutional handlers.

U.S.-domiciled GMP manufacturing maintains molecular specifications (MW 306.44) matching FDA historical reference standards while distinguishing legitimate Schedule III pedigree from underground powder conversions exhibiting characteristic ±30% potency variance documented across independent analytics. This authentic prescription-equivalent presentation serves advanced institutional buyers requiring verified batch traceability through serialized lot numbering essential for Form 222 triplicate documentation and state pharmacy board compliance across 50 U.S. jurisdictions plus territories, eliminating grey-market authenticity uncertainty and international customs seizure exposure inherent to non-domestic sourcing.

Ultima-Oxa positions exclusively within verified DEA Schedule III distribution ecosystems targeting licensed institutional clientele demonstrating controlled substance handling protocols under 21 CFR 1301.13 registrant requirements, maintaining strict commercial positioning devoid of therapeutic claims, cycle recommendations, or performance outcome representations characteristic of legitimate CIII workflows.​

Brand & Manufacturer Information

Ultima Pharma USA manufactures DEA Schedule III controlled substances through domestic GMP facilities serving institutional performance networks requiring rigorous DEA registrant verification prior to fulfillment. Oxa 10 mg completes Ultima’s comprehensive oxandrolone dosage continuum (10/25/50 mg) alongside Stan/Primo Tabs enabling precise institutional SKU differentiation while exact Oxandrin-equivalent morphology and CIII-compliant bottling authenticate supply chain legitimacy versus powder-pressed alternatives rejected universally by DEA-registered dispensaries.

Domestic climate-controlled warehousing supports encrypted Form 222 platforms eliminating international customs risk while serialized batch documentation verifies 10 mg potency through independent HPLC assay (90-110% label claim) distinguishing Ultima from non-pharmaceutical origins lacking controlled substance pedigree essential for institutional bulk procurement exceeding 100-unit thresholds subject to DEA quota allocation under 21 CFR 1308.13 scheduling protocols.​

Active Compound Information

Contains oxandrolone (17β-hydroxy-17α-methyl-2-oxa-5α-androstan-3-one), synthetic anabolic-androgenic steroid exhibiting unique C2-oxa substitution conferring ~10:1 anabolic:androgenic dissociation with minimal estrogenic conversion pathways characteristic of 17α-alkylated DHT derivatives enabling oral bioavailability through hepatic first-pass resistance. DEA Schedule III classification under Anabolic Steroid Control Act amendments reflects controlled hepatotoxicity profile, lipid profile disruption potential, and performance dosage escalation beyond original 2.5-10 mg Oxandrin indications discontinued post-FDA market withdrawal.

10 mg strength precisely replicates historical Oxandrin 10 mg (NDC 54396-110-60) therapeutic reference while 50-tablet count supports institutional packaging exceeding standard 30/60-count pharmacy dispensing units. Molecular formula C19H30O3; logP 3.53 indicating optimal oral absorption profile; WADA S1.1 anabolic agent prohibited year-round across all competitive disciplines globally.​

Product Specifications

Quality Control & Testing Standards

10 mg oxandrolone mandates comprehensive USP <621> potency assay (HPLC 90-110% label claim), USP <711> dissolution (Q=85% within 45 minutes), USP <905> uniformity of dosage units, USP <621> related substances testing for 17-epimer impurities, and ICH Q3C residual solvents verification confirming pharmaceutical-grade specifications matching historical Oxandrin monographs. Ultima batch records include independent ISO 17025-accredited CoA documenting C19H30O3 structural confirmation through NMR/IR spectroscopy, chiral purity >99.5%, and absence of 17-keto degradation characteristic of non-GMP conversions.

Institutional 50-tablet configuration incorporates USP <671> Type III HDPE permeation barriers preventing photo-oxidative degradation while 21 CFR 211.137 child-resistant closure satisfies Schedule III dispensary requirements. Domestic stability chambers maintain ICH Q1A(R2) 40°C/75%RH accelerated conditions confirming 36-month shelf-life exceeding underground alternatives exhibiting 40% potency loss within 12 months post-production.​

Intended Use & Market Positioning

Ultima-Oxa 10 mg 50 Tablets serves DEA-registered CIII institutional performance researchers managing prescription-equivalent Schedule III anabolic inventories exclusively through encrypted fulfillment networks requiring Form 222 triplicate accountability. Exact Oxandrin replication excludes pharmaceutical crossover positioning within premium domestic catalogs serving verified institutional clientele demonstrating controlled substance handling protocols under 21 CFR 1304.21 inventory requirements.

Zero administration regimens, cycle protocols, stacking combinations, PCT regimens, therapeutic indications, or performance outcomes represented maintaining strict commercial positioning characteristic of legitimate Schedule III institutional distribution devoid of medical guidance.​

Legal & Regulatory Disclaimer

Oxandrolone constitutes DEA Schedule III controlled substance under 21 USC §812 Controlled Substances Act with non-medical manufacture/distribution/possession/importation subject to federal penalties including up to 5 years imprisonment/$250,000 fines per 21 U.S.C. § 841 plus mandatory minimums for repeat offenses exceeding personal use thresholds (21 U.S.C. § 841(b)(1)(D)).

Institutional handlers assume complete liability for DEA registrant verification, Form 222 documentation, state-controlled substance licensing, 21 CFR 1304.22 biennial inventory reconciliation, theft/loss reporting within 1 business day (21 CFR 1301.76(b)), and jurisdictional compliance across all 50 states/DC/PR. No medical claims, dosing guidance, cycle protocols, or therapeutic representations provided; positioned exclusively as commercial DEA Schedule III substance for registrant institutional handling per 21 CFR 1301.13.​